RDB18232 - pCI-neo-agmPCFT

Sequence (full)	RDB18232zzk01.seq provided by the depositor

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Terms and conditions set forth by the DEPOSITOR	In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to DEPOSITOR and a citation of the literature designated by the DEPOSITOR are requested.(Yamashiro T. et al. Sci. Rep. 9, 18105, 2019) For use of the BIOLOGICAL RESOURCE by a for-profit organization, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. This material is provided “as is” and without any warranty express or implied, including any warranty of merchantability or fitness for a particular purpose or that the use of the material will not infringe or violate any patent or other intellectual property rights of any third party or that the material will not pose a health or safety risk. The DEPOSITOR shall not be liable for any use of the material by the RECIPIENT, or for any loss, claim, damage, or liability of any kind or nature, which may arise from or in connection with this agreement or from the use, handling, or storage of the material.
Ordering	Please visit Information of Request for Distribution.[link] Order form [Credit Card Payment] [Bank Transfer Payment] Material Transfer Agreement (MTA for use for not-for-profit academic purpose) [Word]
Remarks	Common marmoset is one of the animals as the object of Convention on International Trade in Endangered Species (CITES). Therefore, the permissions from the regulatory bodies are necessary in both exporting and importing countries.

提供案内 (日本国内)

[open/close]

提供条件	利用者は、研究成果の公表にあたって寄託者への謝辞の表明を必要とし、寄託者の指定する文献を引用すること(Yamashiro T. et al. Sci. Rep. 9, 18105, 2019)。営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。当該利用者によるリソースの利用が第三者の産業財産権をはじめとする一切の知的財産権を侵害しない旨の保証をせず、かつ商品性又は特定目的への適合性の保証をしない。また、当該利用者による本件成果有体物の使用、保有によって発生した如何なる結果、損害についても一切その責任を負担せず、かつ、如何なる損害賠償義務（直接、間接損害を問わない。）も負わない。
提供依頼	手続きの詳細は、「提供申込みについて[link]」をご覧ください。提供依頼書 [Word] 提供同意書 (MTA、非営利機関による非営利学術研究用)[Word]
備考	本件クローンの輸出にはワシントン条約に係る手続きが必要です。

References and tips

QC test results

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB18232	pCI-neo-agmPCFT	DNA solution

original	Yamashiro, T., Identification of the amino acid residue responsible for the myricetin sensitivity of human proton-coupled folate transporter. Sci. Rep. 9 (1): 18105 (2019). PMID 31792273.

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check

icon as well as clone information before placing your order.

Primer: chimeric intron 3-prime Region: T7 pro, insert 5' Sequence file: RDB18232_B0Fua.seq
>D07213A3_B0Fu_2_chimeric intron 3-prime_H01_08_ABI08.ab1 1 NNNNNNNNNN NNNNNNNNNN NNNNCNGCTC TTANGGCTAG AGTACTTAAT ACGACTCACT 61 ATAGGCTAGC CTCGAGAATT CAGACATGGA GGGGAGCGCG AGTCCCCCGG ACAAGCCCCG 121 CGCCCGTCCC GCGGCTGCTG TGCTGTGCCG GGGCCCGGTA GAGCCGCTGG TCTTCCTGGC 181 CAACTTTGCC TTGGTCCTGC AGGGCCCGCT CACCACGCAG TATCTGTGGC ACCGCTTCAG 241 TGCCGACCTC GGCTACAATG GCACCCGCCA AAGGGGGGGC TGCAGCAACC GCAGCGCGGA 301 CCCCACCATG CAGGAAGTGG AGACCCTTAC TTCCCACTGG ACCCTCTACA TGAACGTGGG 361 CGGCTTCCTG GTGGGGCTCT TCTCGTCCAC CCTGCTGGGA GCTTGGAGCG ACAGTGTGGG 421 CCGCCGCCCG CTGCTAGTGC TGGCCTCGCT GGGCCTGCTG CTCCAGGCCC TAGTGTCCAT 481 CTTTGTGGTG CAGCTACAGC TCCACGTCGG CTACTTCGTG TTGGGTCGCA TCCTTTGTGC 541 CCTCCTCGGC GACTTCGGTG GCCTTCTGGC TGCTAGCTTT GCGTCCGTGG CAGATGTCAG 601 CTCCAGCCGC AGCCGCACCT TCCGGATGGC CCTGCTGGAA GCCAGCATCG GGGTGGCTGG 661 GATGCTGGCA AGCCTCCTTG GGGGCCACTG GCTCCGGGCC CAGGGTTATG CCAACCCCTT 721 CTGGCTGGCC TTAGCCTTGC TGATAGCCAT GACACTCTAT GCANCTTTCT GCTTTGGTGA 781 GANCTTAAAG GAGCNNAAGT CCACCCGGCT CTTCACGTTC CGTCNCCACC GATCCATTGT 841 CCAGCTCTAT GTGGNTCCAG CCNCNNANAA NTCCANNAAN CATTTAGCCC TGNANTCACN 901 GGNNNNCTTC GNNNTGATCA CTGTGCACTT TGGGGGCCNN NNANATCTTN NCCNTGTNTG 961 AANNGANCAC ACCCCTCNGC NNGGANTNNN NANNANNCNN NNNTNNNTCT GNNNNNNANN 1021 NNNNNNNN //
Primer: pAxCALNLF1 Region: T3 pro, insert 3' Sequence file: RDB18232_B0Fub.seq
>D07213A3_B0Fu_2_pAxCALNLF1_B05_05_ABI24.ab1 1 NNNNNNNNNN NNNNNNNNNG NCTGCTCGNN NCNNTAACCC TCACTAAAGG GAAGCGGCCG 61 CCCGGGTCGA CTCTAGAATC AGGGGCTCTG GGGAAACTGC TGGAACTCAG GGTGAGGAAC 121 AGCCTTTTCC AGCATCCCAA TCAGAACGGC CGGGATGAGC AGGAGGCCAG CTCCCAGGAG 181 GAAGGGGAAC CCCTTCATAA AGTTCAGAGT GGCTGGGTAG AGTGAGTTGA AGATGCCGGA 241 GGCCGTCAGC ATGGCCAGGT TATTCACACA GGCCACAGCA GAAAAGAGAG CACCCTGCTC 301 TGTCTCTCTC ACCAGCTTGG AGAGTTTAGC CCGGATGACA GGTGTGATGA CCAATGACAG 361 GAAGAGCAAC CCATATCCTG TGAACATGAG AGGCGTGATG GTGGCAAAGG CAAAGACCAC 421 CATCCCCAGG ATGTTGAAGG CCAGGCCGAT CTCAGCCACC CAGGCATCGG CCAGGCAGTG 481 CTGCAGGAGC TTCAGGACCA GCAGGCTGGT GAGGTAGGGG AGATGCTGAG CTGCAGAACC 541 ATAGCCGATT AGTCTGGAGT CCCAGCAGAG GGGTGTGCTC AGTTCATACA GGGTCAAGAT 601 GTCCTGGGCC CCAAAGTGCA CAGTGATCAC CACGAAGATG GCCAGTGAGT ACAGGGCTAA 661 ATGCTTCCTG GANTTCTCTG GGGCTGGANC CACATAGAGC TGGNCAATGG ATCGGTGGTG 721 ANGGAACGNG AAGANCCGGG NGGANTTNNG CTCCTTTAAN GTCTCACCAA AGCANAAAGC 781 TGCATANANN GTCATGGCTA TCANCAAGGN NNANNNCAGC CAGNANNNNT TNGNATAACC 841 CNNNNNCNNG ANNNNNNNNN CCCNNANNNA NNNTNGNNAN CATCCCNNNN NNNNNN //
Primer: SV40pro_ori_F Region: SV40pro_ori, NeoR_KanR Sequence file: RDB18232_B0Fuc.seq
>D07213A3_B0Fu_2_SV40pro_ori_F_C05_08_ABI24.ab1 1 NNNNNNNNNN NNNNNNNNNN NGCCTCGGCC TCTGNNCTAN NNNNNAAGTA GTGAGGAGGC 61 TTTTTTGGAG GCCTAGGCTT TTGCAAAAAG CTTGATTCTT CTGACACAAC AGTCTCGAAC 121 TTAAGGCTAG AGCCACCATG ATTGAACAAG ATGGATTGCA CGCAGGTTCT CCGGCCGCTT 181 GGGTGGAGAG GCTATTCGGC TATGACTGGG CACAACAGAC AATCGGCTGC TCTGATGCCG 241 CCGTGTTCCG GCTGTCAGCG CAGGGGCGCC CGGTTCTTTT TGTCAAGACC GACCTGTCCG 301 GTGCCCTGAA TGAACTGCAG GACGAGGCAG CGCGGCTATC GTGGCTGGCC ACGACGGGCG 361 TTCCTTGCGC AGCTGTGCTC GACGTTGTCA CTGAAGCGGG AAGGGACTGG CTGCTATTGG 421 GCGAAGTGCC GGGGCAGGAT CTCCTGTCAT CTCACCTTGC TCCTGCCGAG AAAGTATCCA 481 TCATGGCTGA TGCAATGCGG CGGCTGCATA CGCTTGATCC GGCTACCTGC CCATTCGACC 541 ACCAAGCGAA ACATCGCATC GAGCGAGCAC GTACTCGGAT GGAAGCCGGT CTTGTCGATC 601 AGGATGATCT GGACGAAGAG CATCAGGGGC TCGCGCCAGC CGAACTGTTC GCCAGGCTCA 661 AGGCGCGCAT GCCCGACGGC GANGATCTCG TCGTGANCCA TGGCGATGCC TGCTTGCCGA 721 ATATCATGGT GGAAAATGGC CGCTTTTCTG GANTCATCGA CNGTGGCCGG CTGGGNGTGG 781 CGGANCGCTA TCNNGACATA GCGTTNGCTA CCNNNGNNAT TGCTGANNAN CTTGGCGGNN 841 AANGGGCNNN NCGCTTCCTC NNGCTTTNNN NNANCNCCGC TNCNGANNCN CANNNCANNG 901 NCNTNCTANN GNNNTNNNNN ANNNNNTNNT NNNNNNCGGG NNNCNNNGGG NNNNNNANNN 961 NNNNGNNNNN NNNNN //

pCI-neo-agmPCFT

Distribution information

References and tips

QC test results

References